Early Treatment Pathways Improve Outcomes in Severe Autoimmune Diseases: Systematic Review and Evidence Synthesis of 430 Studies (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2903; Pres time: Nov 10, 2026; 04:00 PM - 04:15 PM; Location: W206; In Person; "Rituximab maintenance therapy significantly reduced relapse compared with azathioprine (HR 0.36, 95% CI 0.23-0.57), while avacopan-based protocols achieved sustained remission in 71.0% versus 56.1% of patients receiving conventional glucocorticoid regimens (difference 12.5%, 95% CI 2.6-22.3; p=0.007). In EGPA, mepolizumab significantly increased remission rates (OR 12.0, 95% CI 2.7-53.0). In SSc-ILD, nintedanib reduced annual forced vital capacity decline by 41 mL/year and multiple trials demonstrated preservation of pulmonary function with cyclophosphamide-, mycophenolate-, and tocilizumab-based treatment protocols. In SLE, anifrolumab improved BICLA response rates versus placebo (59.4% vs 43.9%; p=0.02), while lupus nephritis studies demonstrated significant reductions in adverse renal outcomes (HR 0.12, 95% CI 0.031-0.39).Overall, evidence supporting morbidity reduction (184 studies) exceeded evidence for mortality reduction (122 studies), indicating that..."
Review • ANCA Vasculitis • Dermatomyositis • Eosinophilic Granulomatosis With Polyangiitis • Glomerulonephritis • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Langerhans Cell Histiocytosis • Lupus • Lupus Nephritis • Myositis • Nephrology • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Scleroderma • Systemic Sclerosis • Vasculitis • IFIH1
|
|
Sara Campos1; Marta Baião1; Paula Mesquita1; Carolina Anjo1; Renata Martinho1; Marta Barrigas1; Beatriz Martinho1; Rita Matos Sousa1; Maria Leonor Neves1; Marta Cunha1; Luísa Viveiros2; Teresa Mendonça1; António Marinho1; Marta Casal Moura2
|